American Journal of Criminal Justice

Springer Nature
Springer Nature
ISSN: 10662316, 19361351

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
SCImago
Q1
WOS
Q2
Impact factor
1.8
SJR
1.669
CiteScore
11.3
Categories
Law
Areas
Social Sciences
Years of issue
1975-1976, 1979-1982, 1984-1991, 1993-1997, 2009-2025
journal names
American Journal of Criminal Justice
AM J CRIM JUSTICE
Publications
1 326
Citations
16 107
h-index
53
Top-3 citing journals
Top-3 organizations
University of Louisville
University of Louisville (87 publications)
Florida State University
Florida State University (46 publications)
University of Central Florida
University of Central Florida (46 publications)
Top-3 countries
USA (1136 publications)
Canada (11 publications)
United Kingdom (11 publications)

Most cited in 5 years

Found 
from chars
Publications found: 24792
Corrigendum to ‘OA09.04 Osimertinib with or without SRS for Brain Metastases from EGFRm NSCLC: Pooled Analysis of Two RCTs’ [Journal of Thoracic Oncology Vol. 19 No. 10S (2024) S28]
Ho C., Soon Y.Y., Nichol A., Robledo K., Sahgal A., Pinkham M., Melosky B., Huang Y., Parmar A., Solomon B., Liu M., Tham I.W., Sacher A., Tey J.C., Menjak I., et. al.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC with PD-L1 Expression ≥50%: 5-Year Outcomes of EMPOWER-Lung 1
Kilickap S., Baramidze A., Sezer A., Özgüroğlu M., Gumus M., Bondarenko I., Gogishvili M., Nechaeva M., Schenker M., Cicin I., Fuang H.G., Kulyaba Y., Zyuhal K., Scheusan R., Garassino M.C., et. al.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON)
Hakozaki T., Tanaka K., Shiraishi Y., Sekino Y., Mitome N., Okuma Y., Aiba T., Utsumi T., Tanizaki J., Azuma K., Hara S., Morita R., Niho S., Yokoyama T., Toyozawa R., et. al.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Selective depletion of CCR8+Treg cells enhances anti-tumor immunity of cytotoxic T cells in lung cancer via dendritic cells
Chen P., Wang H., Tang Z., Shi J., Cheng L., Zhao C., Li X., Zhou C.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Reply to: “AI Technologies for Patients With Immune-Related Adverse Events”
O’Reilly D., O’Leary C., Naidoo J.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
In this issue
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Navigating the Complexity of Cerebral Prophylaxis: A Path Worth Taking?
Ramella S., Fiore M., D’Angelillo R.M.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Reducing pERKs to Break “RAS”istance to Sotorasib
Gray S.G., O’Connor D., Mutti L., Meirson T.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Predictive Biomarker for SCLC Therapeutics: A Broken Promise or a Complex Disease With Missing Links
Chu Q.S.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Enlarging the Reach of Screening and Early Detection of Lung Cancer
Brown M., Myers R., Lam S.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
A Response to the Letter to the Editor: “Reply to Lei Wu et al.”
Kim E.K., Bak M.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Accurate Risk Factors of Cardiotoxicity in Patients With NSCLC Treated With Osimertinib
Wu L., Liu N., Sun M.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Patients With Resectable NSCLC Undergoing Neoadjuvant Chemoimmunotherapy: To Adjuvant or Not to Adjuvant?
Wu P., Li D., Zhang C., Sun N., He J.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 1
Artificial Intelligence Technologies for Managing High-Risk Patients With Immune-Related Adverse Events and Optimizing Timing
Liu F., Li H.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0

Top-100

Citing journals

100
200
300
400
500
600
700
Show all (70 more)
100
200
300
400
500
600
700

Citing publishers

500
1000
1500
2000
2500
3000
3500
4000
Show all (70 more)
500
1000
1500
2000
2500
3000
3500
4000

Publishing organizations

10
20
30
40
50
60
70
80
90
Show all (70 more)
10
20
30
40
50
60
70
80
90

Publishing organizations in 5 years

2
4
6
8
10
12
14
16
18
Show all (70 more)
2
4
6
8
10
12
14
16
18

Publishing countries

200
400
600
800
1000
1200
USA, 1136, 85.67%
United Kingdom, 11, 0.83%
Canada, 11, 0.83%
Australia, 10, 0.75%
Saudi Arabia, 6, 0.45%
Ireland, 3, 0.23%
Germany, 2, 0.15%
Kazakhstan, 2, 0.15%
China, 2, 0.15%
Austria, 2, 0.15%
Israel, 2, 0.15%
India, 2, 0.15%
Italy, 2, 0.15%
Cyprus, 2, 0.15%
Netherlands, 2, 0.15%
New Zealand, 2, 0.15%
Republic of Korea, 2, 0.15%
Finland, 2, 0.15%
Czech Republic, 2, 0.15%
Japan, 2, 0.15%
USSR, 2, 0.15%
Bulgaria, 1, 0.08%
Nigeria, 1, 0.08%
Thailand, 1, 0.08%
Sweden, 1, 0.08%
South Africa, 1, 0.08%
200
400
600
800
1000
1200

Publishing countries in 5 years

50
100
150
200
250
USA, 237, 86.81%
Australia, 5, 1.83%
Saudi Arabia, 4, 1.47%
Germany, 2, 0.73%
Kazakhstan, 2, 0.73%
China, 2, 0.73%
Austria, 2, 0.73%
India, 2, 0.73%
Ireland, 2, 0.73%
Cyprus, 2, 0.73%
Finland, 2, 0.73%
Czech Republic, 2, 0.73%
Japan, 2, 0.73%
Bulgaria, 1, 0.37%
United Kingdom, 1, 0.37%
Israel, 1, 0.37%
Italy, 1, 0.37%
Canada, 1, 0.37%
Netherlands, 1, 0.37%
New Zealand, 1, 0.37%
Republic of Korea, 1, 0.37%
Sweden, 1, 0.37%
50
100
150
200
250